Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C

Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B

(2010) H. L.-Y. Chan et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline

(2010) Milan J. Sonneveld et al.   HEPATOLOGY

Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients

(2010) Teerha Piratvisuth et al.   HEPATOLOGY

Factors That Predict Response of Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B to Peginterferon-Alfa

(2009) Erik H.C.J. Buster et al.   GASTROENTEROLOGY

Chronic hepatitis B: Update 2009

(2009) Anna S. F. Lok et al.   HEPATOLOGY

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

(2008) Yun-Fan Liaw et al.   Hepatology International

EASL Clinical Practice Guidelines: Management of chronic hepatitis B

(2008)   JOURNAL OF HEPATOLOGY